Want to see BCLI full AI Analyst Report?
BCLI Stock Chart & Stats
$0.57
-$0.17(-7.46%)
At close: 4:00 PM EST
$0.57
-$0.17(-7.46%)
Day’s Range― - ―
52-Week Range$0.46 - $1.69
Previous CloseN/A
Volume34.73K
Average Volume (3M)22.93K
Market Cap
$12.58M
Enterprise Value$10.85M
Total Cash (Recent Filing)$15.00K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding11,034,775
10 Day Avg. Volume25,343
30 Day Avg. Volume22,935
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-127.68
Enterprise Value/Ebitda-1.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advocacy And SupportThere is growing support for NurOwn's approval, driven by media coverage and independent advocacy, including a Citizens' Petition.
Regulatory ProgressThe P3b study in ALS has been cleared by FDA, and the company plans to conduct the study under the Special Protocol Assessment.
Bears Say
Capital NeedsBrainStorm reported a net loss and will need to raise additional capital to move forward with the P3b study of NurOwn.
Financial ChallengesThe company needs to raise capital and the delisting along with the sharp decline in the share price increases the risk of an incrementally dilutive financing.
Brainstorm Cell Therapeutics News
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.46 and its highest was $1.69 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $12.58M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 38 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on May 15, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.19.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Overvalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 11,034,775 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Technical Analysis
AIM ImmunoTech
―
Alaunos Therapeutics
―
―
PharmaCyte Biotech
―
Cyclerion Therapeutics
―
Ownership Overview
27.45% Insiders
0.03% Mutual Funds
1.32% Other Institutional Investors
71.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---